KPIs & Operating Metrics(New)
Abecma Revenue By GeographyAbecma Revenue By Geography AnnualAbraxane Revenue By GeographyAbraxane Revenue By Geography AnnualBaraclude Revenue By GeographyBaraclude Revenue By Geography AnnualBreakdown Of AssetsBreyanzi Revenue By GeographyBreyanzi Revenue By Geography AnnualCamzyos Revenue By GeographyCamzyos Revenue By Geography AnnualCost Of Products SoldEliquis Revenue By GeographyEliquis Revenue By Geography AnnualEmpliciti Revenue By GeographyEmpliciti Revenue By Geography AnnualEmployee StatisticsGross Margin %Gross ProfitGross Revenue By Wholeseller %Income Before Income TaxInrebic Revenue By GeographyInrebic Revenue By Geography AnnualMature And Other Products Revenue By GeographyMature And Other Products Revenue By Geography AnnualNon Gaap ProfitabilityNon Gaap Profitability %Non Gaap Profitability AnnualNon Gaap Profitability Annual %Onureg Revenue By GeographyOnureg Revenue By Geography AnnualOpdivo Ex U.S Sales Mix %Opdivo Revenue By GeographyOpdivo Revenue By Geography AnnualOpdivo U.S Sales Mix %Opdualag Revenue By GeographyOpdualag Revenue By Geography AnnualOperating Expense SegregationOpex As A % Of Total Revenue %Orencia Revenue By GeographyOrencia Revenue By Geography AnnualOther Brands Revenue By GeographyOther Brands Revenue By Geography AnnualPomalyst/Imnovid Revenue By GeographyPomalyst/Imnovid Revenue By Geography AnnualProduct SalesProduct Sales Mix %Property, Plant & Equipment BreakdownR&D Locations By Geographic AreaReblozyl Revenue By GeographyReblozyl Revenue By Geography AnnualRemaining Performance ObligationRevenue By BrandRevenue By Brand %Revenue By Brand AnnualRevenue By Brand Annual %Revenue By CategoryRevenue By Category %Revenue By Category AnnualRevenue By Category Annual %Revenue By ProductRevenue By Product %Revenue By RegionRevenue By Region %Revenue By Region AnnualRevenue By Region Annual %Revenue By SegmentRevenue By Segment AnnualRevenue By Segment Annual %Revlimid Revenue By GeographyRevlimid Revenue By Geography AnnualSotyktu Revenue By GeographySotyktu Revenue By Geography AnnualSprycel Revenue By GeographySprycel Revenue By Geography AnnualVidaza Revenue By GeographyVidaza Revenue By Geography AnnualYervoy Revenue By GeographyYervoy Revenue By Geography AnnualZeposia Revenue By GeographyZeposia Revenue By Geography Annual
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurent Deferred Tax LiabilityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent TaxesDividends payablesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Assets (QoQ)Assets Growth (1y)Assets Growth (3y)Assets Growth (5y)Capital Expenditures (QoQ)Capital Expenditures Growth (1y)Capital Expenditures Growth (3y)Capital Expenditures Growth (5y)Cash & Equivalents (QoQ)Cash & Equivalents Growth (1y)Cash & Equivalents Growth (3y)Cash & Equivalents Growth (5y)Cash from Investing Activities (QoQ)Cash from Investing Activities Growth (1y)Cash from Investing Activities Growth (3y)Cash from Investing Activities Growth (5y)Cash from Operations (QoQ)Cash from Operations Growth (1y)Cash from Operations Growth (3y)Cash from Operations Growth (5y)Dividends Paid - Common (QoQ)Dividends Paid - Common Growth (1y)Dividends Paid - Common Growth (3y)Dividends Paid - Common Growth (5y)Dividends payables (QoQ)Dividends payables Growth (1y)Dividends payables Growth (3y)Dividends payables Growth (5y)EBIT (QoQ)EBIT Growth (1y)EBIT Growth (3y)EBIT Growth (5y)EBIT Margin (QoQ)EBIT Margin Growth (1y)EBIT Margin Growth (3y)EBIT Margin Growth (5y)EBITDA Margin (QoQ)EBITDA Margin Growth (1y)EBITDA Margin Growth (3y)EBITDA Margin Growth (5y)EBT (QoQ)EBT Growth (1y)EBT Growth (3y)EBT Growth (5y)EBT Margin (QoQ)EBT Margin Growth (1y)EBT Margin Growth (3y)EBT Margin Growth (5y)EPS (Basic) (QoQ)EPS (Basic) Growth (1y)EPS (Basic) Growth (3y)EPS (Basic) Growth (5y)EPS (Weighted Average and Diluted) (QoQ)EPS (Weighted Average and Diluted) Growth (1y)EPS (Weighted Average and Diluted) Growth (3y)EPS (Weighted Average and Diluted) Growth (5y)Enterprise Value (QoQ)Enterprise Value Growth (1y)Enterprise Value Growth (3y)Enterprise Value Growth (5y)FCF Margin (QoQ)FCF Margin Growth (1y)FCF Margin Growth (3y)FCF Margin Growth (5y)FCF Payout Ratio (QoQ)FCF Payout Ratio Growth (1y)FCF Payout Ratio Growth (3y)FCF Payout Ratio Growth (5y)Free Cash Flow (QoQ)Free Cash Flow Growth (1y)Free Cash Flow Growth (3y)Free Cash Flow Growth (5y)Gross Margin (QoQ)Gross Margin Growth (1y)Gross Margin Growth (3y)Gross Margin Growth (5y)Gross Profit (QoQ)Gross Profit Growth (1y)Gross Profit Growth (3y)Gross Profit Growth (5y)Interest Coverage Ratio Growth (1y)Net Cash Flow (QoQ)Net Cash Flow Growth (1y)Net Cash Flow Growth (3y)Net Cash Flow Growth (5y)Net Income (QoQ)Net Income Growth (1y)Net Income Growth (3y)Net Income Growth (5y)Net Income towards Common Stockholders (QoQ)Net Income towards Common Stockholders Growth (1y)Net Income towards Common Stockholders Growth (3y)Net Income towards Common Stockholders Growth (5y)Net Margin (QoQ)Net Margin Growth (1y)Net Margin Growth (3y)Net Margin Growth (5y)Operating Income (QoQ)Operating Income Growth (1y)Operating Income Growth (3y)Operating Income Growth (5y)Operating Margin (QoQ)Operating Margin Growth (1y)Operating Margin Growth (3y)Operating Margin Growth (5y)Profit After Tax (QoQ)Profit After Tax Growth (1y)Profit After Tax Growth (3y)Profit After Tax Growth (5y)Property, Plant & Equipment (Net) (QoQ)Property, Plant & Equipment (Net) Growth (1y)Property, Plant & Equipment (Net) Growth (3y)Property, Plant & Equipment (Net) Growth (5y)Return on Assets (QoQ)Return on Assets Growth (1y)Return on Assets Growth (3y)Return on Assets Growth (5y)Return on Capital Employed (QoQ)Return on Capital Employed Growth (1y)Return on Capital Employed Growth (3y)Return on Capital Employed Growth (5y)Return on Equity (QoQ)Return on Equity Growth (1y)Return on Equity Growth (3y)Return on Equity Growth (5y)Return on Invested Capital (QoQ)Return on Invested Capital Growth (1y)Return on Invested Capital Growth (3y)Return on Invested Capital Growth (5y)Return on Sales (QoQ)Return on Sales Growth (1y)Return on Sales Growth (3y)Return on Sales Growth (5y)Revenue (QoQ)Revenue Growth (1y)Revenue Growth (3y)Revenue Growth (5y)Share-based Compensation (QoQ)Share-based Compensation Growth (1y)Share-based Compensation Growth (3y)Share-based Compensation Growth (5y)Shareholder's Equity (QoQ)Shareholder's Equity Growth (1y)Shareholder's Equity Growth (3y)Shareholder's Equity Growth (5y)Tax Rate (QoQ)Tax Rate Growth (1y)Tax Rate Growth (3y)Tax Rate Growth (5y)Total Debt (QoQ)Total Debt Growth (1y)Total Debt Growth (3y)Total Debt Growth (5y)
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables RefundsShares IssuedShares OutstandingShares RepurchasedShort-Term Debt issuances
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned
Bristol Myers Squibb (BMY) Long-Term Debt Issuances (2016 - 2025)
Generated on {Timestamp}
© BusinessQuant.com
Generated on {Timestamp}
Powered by 
Historic Long-Term Debt Issuances for Bristol Myers Squibb (BMY) over the last 10 years, with Q4 2025 value amounting to $5.7 billion.
- Bristol Myers Squibb's Long-Term Debt Issuances changed N/A to $5.7 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $5.7 billion, marking a year-over-year decrease of 5544.52%. This contributed to the annual value of $5.7 billion for FY2025, which is 5544.52% down from last year.
- Per Bristol Myers Squibb's latest filing, its Long-Term Debt Issuances stood at $5.7 billion for Q4 2025.
- In the past 5 years, Bristol Myers Squibb's Long-Term Debt Issuances registered a high of $12.9 billion during Q1 2024, and its lowest value of $4.5 billion during Q4 2023.
- Over the past 4 years, Bristol Myers Squibb's median Long-Term Debt Issuances value was $5.8 billion (recorded in 2022), while the average stood at $7.3 billion.
Peer Comparison
Historic Data
Download Data 🔒| Date | Value |
|---|---|